Biomarkers as a guide of medical treatment in cardiovascular diseases

Current Medicinal Chemistry

Volumn 19, Issue 16, 2012, Pages 2485-2496

  Vavuranakis, M ^a   Kariori, M G ^a   Kalogeras, K I ^a   Vrachatis, D A ^a   Moldovan, C ^a   Tousoulis, D ^a   Stefanadis, C ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

BNP; CTnI; CTnT; HsCRP; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATORVASTATIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GALECTIN 3; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TROPONIN C; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIAGNOSTIC ACCURACY; EARLY INTERVENTION; ECHOCARDIOGRAPHY; HEART FAILURE; IMMUNOASSAY; INFLAMMATION; LIFESTYLE MODIFICATION; MEDICAL HISTORY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TREATMENT RESPONSE;

EID: 84860746854     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800492977     Document Type: Article

References (146)

1. Ahmed, N., Clinical biochemistry. Fundamentals of biomedical science. 2011, Oxford: Oxford University Press. xxv, 714 p.
2. Tousoulis, D. et al. New biochemical markers in acute coronary syndromes. Curr Med Chem, 2008, 15(13), 1288-96. (Pubitemid 351997798)
3. Thygesen, K., et al, Universal definition of myocardial infarction. Circulation, 2007. 116(22): p. 2634-53. (Pubitemid 350182388)
4. Giannitsis, E. and H. Katus, Current Recommendations for Interpretation of the Highly Sensitive Troponin T Assay for Diagnostic, Therapeutic and Prognostic Purposes in Patients with a Non-ST-segment-elevation Acute Coronary Syndrome | Cardiology. European Cardiology. 5: p. 44.
5. Giannitsis, E., et al, Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem, 2010. 56(2): p. 254-61.
6. Cummins, B., M.L. Auckland, and P. Cummins, Cardiac-specific troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction. Am Heart J, 1987. 113(6): p. 1333-44. (Pubitemid 17092802)
7. Katus, H.A., et al, Development and in vitro characterization of a new immunoassay of cardiac troponin T. Clin Chem, 1992. 38(3): p. 386-93.
8. Bodor, G.S., et al, Development of monoclonal antibodies for an assay of cardiac troponin-I and preliminary results in suspected cases of myocardial infarction. Clin Chem, 1992. 38(11): p. 2203-14.
9. Muller-Bardorff, M., et al, Improved troponin T ELISA specific for cardiac troponin T isoform: assay development and analytical and clinical validation. Clin Chem, 1997. 43(3): p. 458-66. (Pubitemid 27106481)
10. Collinson, P.O., N. Wiggins, and D.C. Gaze, Clinical evaluation of the ACS:180 cardiac troponin I assay. Ann Clin Biochem, 2001. 38(Pt 5): p. 509-19. (Pubitemid 32846056)
11. Morrow, D.A., et al, Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA, 2001. 286(19): p. 2405-12. (Pubitemid 33098158)
12. Stefanadis, C. et al. Vulnerable plaque: the challenge to identify and treat it. J Interv Cardiol. 2003, 16(3), 273-80. (Pubitemid 36667909)
13. Keller, T., et al, Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med, 2009. 361(9): p. 868-77.
14. Lindahl, B., P. Venge, and L. Wallentin, Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol, 1997. 29(1): p. 43-8. (Pubitemid 27028718)
15. Morrow, D.A., et al, Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol, 2000. 36(6): p. 1812-7.
16. Newby, L.K., et al, Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation, 2001. 103(24): p. 2891-6. (Pubitemid 32578124)
17. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet, 1999. 354(9180): p. 708-15.
18. Januzzi, J.L., Jr., et al, High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation, 2010. 121(10): p. 1227-34.
19. Mingels, A., et al, Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin Chem, 2009. 55(1): p. 101-8.
20. Melanson, S.E., D.A. Morrow, and P. Jarolim, Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am J Clin Pathol, 2007. 128(2): p. 282-6. (Pubitemid 47262627)
21. Apple, F.S., et al, Use of the Centaur TnI-Ultra assay for detection of myocardial infarction and adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem, 2008. 54(4): p. 723-8. (Pubitemid 351573705)
22. Reichlin, T., et al, Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med, 2009. 361(9): p. 858-67.
23. Morrow, D.A., et al, National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation, 2007. 115(13): p. e356-75. (Pubitemid 46648624)
24. Reiter, M., et al, Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. Eur Heart J, 2011. 32(11): p. 1379-89.
25. Okamatsu, K., et al, Elevated troponin T levels and lesion characteristics in non-ST-elevation acute coronary syndromes. Circulation, 2004. 109(4): p. 465-70. (Pubitemid 38168507)
26. Wong, G.C., et al, Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation, 2002. 106(2): p. 202-7.
27. de Winter, R.J., Risk stratification with cardiac troponin I in acute coronary syndromes. J Am Coll Cardiol, 2000. 36(6): p. 1824-6.
28. Boersma, E., et al, Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet, 2002. 359(9302): p. 189-98. (Pubitemid 34113814)
29. Damman, P., et al, 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol, 2010. 55(9): p. 858-64.
30. Jessup, M., et al, 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation, 2009. 119(14): p. 1977-2016.
31. Diderholm, E., et al, The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. Am Heart J, 2002. 143(5): p. 760-7. (Pubitemid 34595331)
32. Fuchs, S., et al, Cardiac troponin I levels and clinical outcomes in patients with acute coronary syndromes: the potential role of early percutaneous revascularization. J Am Coll Cardiol, 1999. 34(6): p. 1704-10.
33. Cannon, C.P., et al, Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med, 2001. 344(25): p. 1879-87. (Pubitemid 32564900)
34. Authors/Task Force, M., et al, ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2011. 32(23): p. 2999-3054.
35. Vasan, R.S., Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation, 2006. 113(19): p. 2335-62. (Pubitemid 43947980)
36. Kontos, M.C., et al, Troponin-positive, MB-negative patients with non-STelevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry. Am Heart J, 2010. 160(5): p. 819-25.
37. Steg, P.G., G. FitzGerald, and K.A. Fox, Risk stratification in non-STsegment elevation acute coronary syndromes: troponin alone is not enough. Am J Med, 2009. 122(2): p. 107-8.
38. Thygesen, K., et al, Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J, 2010. 31(18): p. 2197-204.
39. Hamm, C.W., et al, Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med, 1997. 337(23): p. 1648-53. (Pubitemid 27510101)
40. Wallace, T.W., et al, Prevalence and determinants of troponin T elevation in the general population. Circulation, 2006. 113(16): p. 1958-65.
41. Kociol, R.D., et al, Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol, 2010. 56(14): p. 1071-8.
42. Lum, G., B. Mushlin, and L. Farney, False-positive rates for the qualitative analysis of urine benzodiazepines and metabolites with the reformulated Abbott Multigent reagents. Clin Chem, 2008. 54(1): p. 220-1. (Pubitemid 351182623)
43. Wu, A.H., et al, National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem, 1999. 45(7): p. 1104-21. (Pubitemid 29340557)
44. Jaffe, A.S., et al, It's time for a change to a troponin standard. Circulation, 2000. 102(11): p. 1216-20.
45. Fox, K.A., et al, British Cardiac Society Working Group on the definition of myocardial infarction. Ann Clin Biochem, 2004. 41(Pt 4): p. 263-71.
46. Stefanadis C. et al. Relation between local temperature and C-reactive protein levels in patients with coronary artery disease: effects of atorvastatin treatment. Aherosclerosis, 2007, 192(2), 396-400. (Pubitemid 46726320)
47. Stefanadis, C. et al. Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes. J Mol Cell Cardiol, 2000. 32(1): p. 43-52. (Pubitemid 30064303)
48. Hingorani, A.D., et al, C-reactive protein and coronary heart disease: predictive test or therapeutic target? Clin Chem, 2009. 55(2): p. 239-55.
49. Koenig, W., Is hsCRP Back on Board? Implications from the JUPITER Trial. Clin Chem, 2009. 55(2): p. 216-8.
50. Osman, R., et al, Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. Vasc Health Risk Manag, 2006. 2(3): p. 221-37. (Pubitemid 44275459)
51. James, S.K., et al, Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol, 2003. 41(6): p. 916-24. (Pubitemid 36315530)
52. Lindahl, B., et al, Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med, 2000. 343(16): p. 1139-47.
53. Caixeta, A., et al, Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial. J Thromb Thrombolysis, 2011. 31(2): p. 154-64.
54. He, L.P., et al, Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies. Heart, 2010. 96(5): p. 339-46.
55. Scirica, B.M., et al, Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem, 2007. 53(10): p. 1800-7. (Pubitemid 47509673)
56. Biasucci, L.M., et al, Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation, 1999. 99(7): p. 855-60. (Pubitemid 29094296)
57. Bogaty, P., et al, Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J Am Coll Cardiol, 2008. 51(24): p. 2339-46. (Pubitemid 351784544)
58. Pasceri, V., J.T. Willerson, and E.T. Yeh, Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 2000. 102(18): p. 2165-8.
59. Verma, S., et al, A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation, 2002. 106(8): p. 913-9. (Pubitemid 34925323)
60. Venugopal, S.K., S. Devaraj, and I. Jialal, C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation, 2003. 108(14): p. 1676-8. (Pubitemid 37243652)
61. Schiele, F., et al, C-reactive protein improves risk prediction in patients with acute coronary syndromes. Eur Heart J, 2010. 31(3): p. 290-7.
62. Morrow, D.A., et al, Clinical relevance of C-reactive protein during followup of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation, 2006. 114(4): p. 281-8. (Pubitemid 44297094)
63. Klingenberg, R. and G.K. Hansson, Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J, 2009. 30(23): p. 2838-44.
64. Sasaki, J., M. Iwashita, and S. Kono, Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb, 2006. 13(3): p. 123-9.
65. Mora, S., et al, Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation, 2010. 121(9): p. 1069-77.
66. Albert, M.A., et al, Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Am Heart J, 2011. 162(1): p. 106-14 e2.
67. Ridker, P.M., et al, Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet, 2009. 373(9670): p. 1175-82.
68. Kaul, S., R.P. Morrissey, and G.A. Diamond, By Jove! What is a clinician to make of JUPITER? Arch Intern Med, 2010. 170(12): p. 1073-7.
69. de Lorgeril, M., et al, Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med, 2010. 170(12): p. 1032-6.
70. Ridker, P.M. and R.J. Glynn, The JUPITER Trial: responding to the critics. Am J Cardiol, 2010. 106(9): p. 1351-6.
71. Ridker, P.M., et al, Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med, 2001. 344(26): p. 1959-65. (Pubitemid 32568149)
72. Hsia, J., et al, Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The jupiter trial (justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin) J Am Coll Cardiol 2011 57 16 1666-75
73. Yang, E.Y., et al, Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol, 2009. 54(25): p. 2388-95.
74. Vaccarino, V., J.D. Bremner, and M.E. Kelley, JUPITER: a few words of caution. Circ Cardiovasc Qual Outcomes, 2009. 2(3): p. 286-8.
75. Slejko, J.F., R.L. Page, 2nd, and P.W. Sullivan, Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. Curr Med Res Opin, 2010. 26(10): p. 2485-97.
76. Ridker, P.M., et al, Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity CReactive Protein. Circulation: Cardiovascular Quality and Outcomes, 2009. 2(6): p. 616-623.
77. Michos, E.D. and R.S. Blumenthal, Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study. J Am Coll Cardiol, 2009. 53(11): p. 931-5.
78. Alehagen, U., et al, Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA, 2011. 305(20): p. 2088-95.
79. Bonow, R.O., et al, ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J Am Coll Cardiol, 2005. 46(6): p. 1144-78. (Pubitemid 41316528)
80. Lloyd-Jones, D., et al, Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation, 2010. 121(7): p. e46-e215.
81. Stafford, R.S. and D.C. Radley, The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol, 2003. 41(1): p. 56-61. (Pubitemid 36044404)
82. Holtzman, C.W., B.S. Wiggins, and S.A. Spinler, Role of P-glycoprotein in statin drug interactions. Pharmacotherapy, 2006. 26(11): p. 1601-7. (Pubitemid 44704473)
83. Braunwald, E., Biomarkers in heart failure. N Engl J Med, 2008. 358(20): p. 2148-59.
84. de Bold, A.J., et al, A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci, 1981. 28(1): p. 89-94. (Pubitemid 11184926)
85. Richards, A.M., et al, Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J, 1993. 69(5): p. 414-7. (Pubitemid 23171117)
86. Yasue, H., et al, Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation, 1994. 90(1): p. 195-203. (Pubitemid 24203680)
87. Magga, J., et al, B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Ann Med, 1998. 30 Suppl 1: p. 39-45. (Pubitemid 28414373)
88. O'Donoghue, M. and E. Braunwald, Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol, 2010. 7(1): p. 13-20.
89. Tang, W.H., et al, National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. Clin Biochem, 2008. 41(4-5): p. 210-21. (Pubitemid 351246749)
90. Felker, G.M., J.W. Petersen, and D.B. Mark, Natriuretic peptides in the diagnosis and management of heart failure. CMAJ, 2006. 175(6): p. 611-7. (Pubitemid 44439724)
91. Fragopoulou, E. et al. N-terminal ProBNP distribution and correlations with biological characteristics in apparently healthy Greek population: ATTICA study. Angiology. 2010, 61(4), 397-404
92. Wang, T.J., et al, Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol, 2002. 90(3): p. 254-8. (Pubitemid 34804560)
93. Wang, T.J., et al, Impact of obesity on plasma natriuretic peptide levels. Circulation, 2004. 109(5): p. 594-600. (Pubitemid 38198866)
94. Anwaruddin, S., et al, Renal function, congestive heart failure, and aminoterminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol, 2006. 47(1): p. 91-7. (Pubitemid 43005170)
95. Wiley, C.L., et al, Association of B-type natriuretic Peptide levels with estimated glomerular filtration rate and congestive heart failure. Clin Med Res, 2010. 8(1): p. 7-12.
96. Jensen, J., et al, Inflammation increases NT-proBNP and the NTproBNP/BNP ratio. Clin Res Cardiol, 2010. 99(7): p. 445-52.
97. Januzzi, J.L., Jr., et al, The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol, 2005. 95(8): p. 948-54. (Pubitemid 40487743)
98. Fonarow, G.C., et al, Admission B-type natriuretic peptide levels and inhospital mortality in acute decompensated heart failure. J Am Coll Cardiol, 2007. 49(19): p. 1943-50. (Pubitemid 46694287)
99. Behnes, M., et al, Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema. Int J Cardiol, 2009. 135(2): p. 165-74.
100. Moe, G.W., et al, N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation, 2007. 115(24): p. 3103-10. (Pubitemid 46956499)
101. Dickstein, K., et al, ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail, 2008. 10(10): p. 933-89.
102. Sheikh, A. and S. Walker, Anaphylaxis. BMJ, 2005. 331(7512): p. 330.
103. Bettencourt, P., et al, N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation, 2004. 110(15): p. 2168-74. (Pubitemid 39372496)
104. Cohen-Solal, A., et al, Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol, 2009. 53(25): p. 2343-8.
105. Michtalik, H.J., et al, Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. Am J Cardiol, 2011. 107(8): p. 1191-5.
106. Anand, I.S., et al, Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation, 2003. 107(9): p. 1278-83. (Pubitemid 36314411)
107. Logeart, D., et al, Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol, 2004. 43(4): p. 635-41. (Pubitemid 38229537)
108. Doust, J.A., et al, How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ, 2005. 330(7492): p. 625.
109. Motwani, J.G., et al, Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet, 1993. 341(8853): p. 1109-13. (Pubitemid 23125853)
110. Latini, R., et al, Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation, 2002. 106(19): p. 2454-8. (Pubitemid 35278801)
111. Tsutamoto, T., et al, Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol, 2001. 37(5): p. 1228-33.
112. Cleland, J.G., et al, The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med, 2005. 352(15): p. 1539-49. (Pubitemid 40517094)
113. Davis, M.E., et al, Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation, 2006. 113(7): p. 977-85. (Pubitemid 43879473)
114. Stanek, B., et al, Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol, 2001. 38(2): p. 436-42. (Pubitemid 32721772)
115. Troughton, R.W., et al, Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet, 2000. 355(9210): p. 1126-30. (Pubitemid 30172933)
116. Jourdain, P., et al, Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol, 2007. 49(16): p. 1733-9. (Pubitemid 46589928)
117. Shah, M.R., et al, The STARBRITE trial: a randomized, pilot study of Btype natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail, 2011. 17(8): p. 613-21.
118. Pfisterer, M., et al, BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA, 2009. 301(4): p. 383-92.
119. Lainchbury, J.G., et al, N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol, 2009. 55(1): p. 53-60.
120. Eurlings, L.W., et al, Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol, 2010. 56(25): p. 2090-100.
121. Berger, R., et al, N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol, 2010. 55(7): p. 645-53.
122. Persson, H., et al, Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure-SIGNAL-HF (Swedish Intervention study-Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail, 2010. 12(12): p. 1300-8.
123. Bhardwaj, A., et al, Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Am Heart J, 2010. 159(4): p. 532-538 e1.
124. Porapakkham, P., et al, B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med, 2010. 170(6): p. 507-14.
125. Peacock, W.F.t., et al, Cardiac troponin and outcome in acute heart failure. N Engl J Med, 2008. 358(20): p. 2117-26.
126. Horwich, T.B., et al, Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation, 2003. 108(7): p. 833-8. (Pubitemid 37022125)
127. Kawahara, C., et al, Prognostic role of high-sensitivity cardiac troponin T in patients with nonischemic dilated cardiomyopathy. Circ J, 2011. 75(3): p. 656-61.
128. Kubo, T., et al, Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy. Circ J, 2011. 75(4): p. 919-26.
129. Anker, S.D., et al, Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation, 2003. 107(15): p. 1991-7. (Pubitemid 36506072)
130. Anand, I.S., et al, C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation, 2005. 112(10): p. 1428-34. (Pubitemid 41291768)
131. Ghali, J.K., et al, Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation, 2008. 117(4): p. 526-35.
132. Belonje, A.M., et al, Endogenous erythropoietin and outcome in heart failure. Circulation, 2010. 121(2): p. 245-51.
133. Kazory, A., Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. Am J Cardiol, 2010. 106(5): p. 694-700.
134. Gotsman, I., et al, The significance of serum urea and renal function in patients with heart failure. Medicine (Baltimore), 2010. 89(4): p. 197-203.
135. Damman, K., et al, Both in-and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). Eur J Heart Fail, 2009. 11(9): p. 847-54.
136. Lok, D.J., et al, Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol, 2010. 99(5): p. 323-8.
137. de Boer, R.A., et al, Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med, 2011. 43(1): p. 60-8.
138. Melendez, G.C., et al, Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension, 2010. 56(2): p. 225-31.
139. Kuwahara, F., et al, Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension, 2004. 43(4): p. 739-45. (Pubitemid 38405580)
140. Collier, P., et al, Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail, 2011. 13(10): p. 1087-95.
141. Makita, K., J. Falck, and J. Capdevila, Cytochrome P450, the arachidonic acid cascade, and hypertension: new vistas for an old enzyme system. The FASEB Journal, 1996. 10(13): p. 1456-1463. (Pubitemid 26384442)
142. Kuklinska, A.M., et al, Diagnostic biomarkers of essential arterial hypertension: the value of prostacyclin, nitric oxide, oxidized-LDL, and peroxide measurements. Int Heart J, 2009. 50(3): p. 341-51.
143. Suzuki, H.I. and K. Miyazono, Dynamics of microRNA biogenesis: crosstalk between p53 network and microRNA processing pathway. J Mol Med (Berl), 2010. 88(11): p. 1085-94.
144. Xiao, J. and Y.H. Chen, MicroRNAs: Novel Regulators of the Heart. J Thorac Dis, 2010. 2(1): p. 43-7.
145. Sibley, C.R. and M.J. Wood, The miRNA pathway in neurological and skeletal muscle disease: implications for pathogenesis and therapy. J Mol Med (Berl), 2011. 89(11): p. 1065-77.
146. Xu, J., et al, Circulating microRNAs: novel biomarkers for cardiovascular diseases. J Mol Med (Berl), 2011.